<p>Ampliphi Biosciences Corp（NYSEAMERICAN:APHB - 獲取免費報告）週三上漲了 9.3%。該股票最高交易價為$9.59，最後交易價為$9.54。在午盤交易中，約有 133,273 股成交，較平均每日成交量 842,200 股下降了 84%。該股票此前收盤價為$8.73。</p>
<p>獲取 <strong>Ampliphi Biosciences</strong> 的提醒：</p>
<h2>Ampliphi Biosciences 股票表現</h2>
<p>該公司的 50 日移動平均線為$6.96，200 日移動平均線為$5.17。</p>
<h2>Ampliphi Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Ampliphi Biosciences, Inc 是一家總部位於馬薩諸塞州劍橋的臨牀階段生物製藥公司，專注於發現和開發新型療法，以預防和治療危及生命的耐藥性感染。公司的核心使命是通過推進首創和最佳抗菌藥物的晚期臨牀試驗，解決日益嚴重的抗生素耐藥性全球威脅。</p>
<p>該公司的主要產品候選藥物 exeporfinium chloride（XF-73）是一種開創性的局部抗菌藥物，旨在為接受高風險手術的患者進行術前鼻腔去殖民化，以去除金黃色葡萄球菌。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Ampliphi Biosciences 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>這讓我感到憤怒</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Ampliphi Biosciences 嗎？</h2>
<p>在考慮 Ampliphi Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Ampliphi Biosciences 並不在名單上。</p>
<p>雖然 Ampliphi Biosciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

醫療業 ETF - SPDR

<p>Ampliphi Biosciences（紐約證券交易所代碼：APHB）的股價上漲了 9.3%，交易價格為 9.54 美元，最高達到 9.59 美元。儘管股價上漲，交易量卻比平均水平下降了 84%，共交易了 133,273 股。該公司專注於開發針對耐藥性感染的治療方案，其主要產品是用於術前鼻腔去殖的 exeporfinium chloride。分析師目前對該股票的評級為持有，暗示可能有更好的投資選擇</p>

<p>Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - Get Free Report) was up 9.3% on Wednesday . The stock traded as high as $9.59 and last traded at $9.54. Approximately 133,273 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 842,200 shares. The stock had previously closed at $8.73.</p>
<div class="lb-trans"><p>Ampliphi Biosciences Corp（NYSEAMERICAN:APHB - 獲取免費報告）週三上漲了 9.3%。該股票最高交易價為$9.59，最後交易價為$9.54。在午盤交易中，約有 133,273 股成交，較平均每日成交量 842,200 股下降了 84%。該股票此前收盤價為$8.73。</p>
</div><p>Get <strong>Ampliphi Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ampliphi Biosciences</strong> 的提醒：</p>
</div><h2>Ampliphi Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Ampliphi Biosciences 股票表現</h2>
</div><p>The business has a 50 day moving average of $6.96 and a 200-day moving average of $5.17.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為$6.96，200 日移動平均線為$5.17。</p>
</div><h2>Ampliphi Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Ampliphi Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company's core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.</p>
<div class="lb-trans"><p>Ampliphi Biosciences, Inc 是一家總部位於馬薩諸塞州劍橋的臨牀階段生物製藥公司，專注於發現和開發新型療法，以預防和治療危及生命的耐藥性感染。公司的核心使命是通過推進首創和最佳抗菌藥物的晚期臨牀試驗，解決日益嚴重的抗生素耐藥性全球威脅。</p>
</div><p>The company's lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 exeporfinium chloride（XF-73）是一種開創性的局部抗菌藥物，旨在為接受高風險手術的患者進行術前鼻腔去殖民化，以去除金黃色葡萄球菌。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Ampliphi Biosciences</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>This makes me furious</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Ampliphi Biosciences 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國的 1776 再次發生</li>
<li>這讓我感到憤怒</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ampliphi Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Ampliphi Biosciences 嗎？</h2>
</div><p>Before you consider Ampliphi Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ampliphi Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ampliphi Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Ampliphi Biosciences 並不在名單上。</p>
</div><p>While Ampliphi Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ampliphi Biosciences 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Ampliphi Biosciences (NYSEAMERICAN:APHB) Trading Up 9.3%  - What's Next?

Market Beat

醫藥突破 ETF - ALPS

醫療業 ETF - Vanguard

標普生物技術 ETF - SPDR

APTOSE BIOSCIENCES INC

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

MBX Biosciences

納斯達克生物科技指數 ETF - iShares Nasdaq

美國制藥 ETF - iShares

Invesco Nasdaq Biotechnology ETF

Ampliphi Biosciences (NYSEAMERICAN:APHB) 股價上漲了 9.3% - 接下來會發生什麼？